T. Dekhtyar

发表

Conserved residues in the coiled-coil pocket of human immunodeficiency virus type 1 gp41 are essential for viral replication and interhelical interaction.

A. Molla, H. Mo, K. Swift, 2004, Virology.

1229 GENOTYPIC AND PHENOTYPIC CHARACTERIZATION OF NS3 VARIANTS SELECTED IN HCV-INFECTED PATIENTS TREATED WITH ABT-450

T. Pilot‐Matias, B. Bernstein, C. Collins, 2011 .

Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection

Liangjun Lu, T. Pilot‐Matias, J. Kort, 2018, Viruses.

In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir

Liangjun Lu, T. Pilot‐Matias, J. Randolph, 2017, Antimicrobial Agents and Chemotherapy.

In Vitro and In Vivo Antiviral Activity and Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor ABT-450

A. Molla, D. Kempf, Liangjun Lu, 2014, Antimicrobial Agents and Chemotherapy.

Synthesis, antiviral activity, and pharmacokinetic evaluation of P3 pyridylmethyl analogs of oximinoarylsulfonyl HIV-1 protease inhibitors.

A. Molla, D. Kempf, H. Mo, 2006, Bioorganic & Medicinal Chemistry.

In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir

D. Kempf, Liangjun Lu, T. Pilot‐Matias, 2017, Antimicrobial Agents and Chemotherapy.

Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir

K. Chayama, T. Pilot‐Matias, M. Burroughs, 2017, Journal of medical virology.

Oximinoarylsulfonamides as potent HIV protease inhibitors.

V. Stoll, D. Kempf, J. Randolph, 2005, Bioorganic & medicinal chemistry letters.

Discovery of imidazolidine-2,4-dione-linked HIV protease inhibitors with activity against lopinavir-resistant mutant HIV.

H. Mo, D. Kempf, K. Marsh, 2006, Bioorganic & Medicinal Chemistry.

Mutations Conferring Resistance to a Hepatitis C Virus (HCV) RNA-Dependent RNA Polymerase Inhibitor Alone or in Combination with an HCV Serine Protease Inhibitor In Vitro

Kent D. Stewart, Teresa Ng, Rubina Mondal, 2005, Antimicrobial Agents and Chemotherapy.

Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan

K. Chayama, T. Pilot‐Matias, M. Burroughs, 2017, Antimicrobial Agents and Chemotherapy.

Resistance selection using glecaprevir and pibrentasvir in replicons of major hepatitis C virus genotypes

T. Pilot‐Matias, T. Reisch, C. Collins, 2017 .

O057 : Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir/r-, ombitasvir- and dasabuvir-based regimens

T. Pilot‐Matias, T. Reisch, W. Xie, 2015 .

Identification of host genes involved in hepatitis C virus replication by small interfering RNA technology

A. Molla, H. Mo, T. Pilot‐Matias, 2007, Hepatology.

A replicon-based shuttle vector system for assessing the phenotype of HCV NS5B polymerase genes isolated from patient populations.

A. Molla, H. Mo, T. Pilot‐Matias, 2007, Journal of virological methods.

Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitro.

H. Mo, T. Pilot‐Matias, K. Stewart, 2007, Antiviral research.

Antiviral interactions of an HCV polymerase inhibitor with an HCV protease inhibitor or interferon in vitro.

A. Molla, H. Mo, T. Ng, 2007, Antiviral research.

Identiﬁcation and Structural Characterization of I84C and I84A Mutations That Are Associated with High-Level Resistance to Human Immunodeﬁciency Virus Protease Inhibitors and Impair Viral Replication (cid:1)

A. Molla, D. Kempf, N. Parkin, 2007 .

Identification and Structural Characterization of I84C and I84A Mutations That Are Associated with High-Level Resistance to Human Immunodeficiency Virus Protease Inhibitors and Impair Viral Replication

A. Molla, D. Kempf, N. Parkin, 2006, Antimicrobial Agents and Chemotherapy.

Characterization of resistant HIV variants generated by in vitro passage with lopinavir/ritonavir.

A. Molla, D. Kempf, H. Mo, 2003, Antiviral research.

Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir

T. Pilot‐Matias, T. Reisch, W. Xie, 2018, PloS one.

Pooled Resistance Analysis in HCV Genotype 1-6 Infected Patients Treated With 1 Glecaprevir / Pibrentasvir in Phase 2 and 3 Clinical Trials 2

T. Pilot‐Matias, T. Reisch, W. Xie, 2018 .

Characterization of demographics and NS5A genetic diversity for hepatitis C virus genotype 4‐infected patients with or without cirrhosis treated with ombitasvir/paritaprevir/ritonavir

T. Pilot‐Matias, T. Reisch, R. Redman, 2018, Journal of viral hepatitis.

Hepatitis C Virus Genotype 4 Resistance and Subtype Demographic Characterization of Patients Treated with Ombitasvir plus Paritaprevir/Ritonavir

T. Pilot‐Matias, T. Reisch, C. Collins, 2015, Antimicrobial Agents and Chemotherapy.

In Vitro Selection and Characterization of Human Immunodeficiency Virus Type 2 with Decreased Susceptibility to Lopinavir

F. Gao, A. Molla, D. Kempf, 2007, Antimicrobial Agents and Chemotherapy.

In Vitro Selection and Characterization of Human Immunodeﬁciency Virus Type 2 with Decreased Susceptibility to Lopinavir (cid:1)

A. Molla, D. Kempf, H. Mo, 2007 .

Hepatitis C Virus Genotype 4 Resistance and Subtype Demographic Characterization of 1

T. Pilot‐Matias, T. Reisch, C. Collins, 2015 .

Synthesis and antiviral activity of P1' arylsulfonamide azacyclic urea HIV protease inhibitors.

V. Stoll, S. Vasavanonda, D. Kempf, 2004, Bioorganic & medicinal chemistry letters.

Highlights of the Structure-Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530).

A. C. Krueger, T. Pilot‐Matias, J. Randolph, 2018, Journal of medicinal chemistry.

Discovery of 2-aminoisobutyric acid ethyl ester (AIBEE) phosphoramidate prodrugs for delivering nucleoside HCV NS5B polymerase inhibitors.

J. Randolph, Hui-ju Chen, Deanne F. Stolarik, 2020, Bioorganic & medicinal chemistry letters.

Synthesis and evaluation of 2'-dihalo ribonucleotide prodrugs with activity against hepatitis C virus.

J. Randolph, R. Henry, Hui-ju Chen, 2019, Bioorganic & medicinal chemistry.

Design and synthesis of pseudo-symmetric HIV protease inhibitors containing a novel hydroxymethylcarbonyl (HMC)-hydrazide isostere.

Y. Kiso, Tooru Kimura, Y. Hayashi, 2003, Bioorganic & medicinal chemistry letters.

Characterization of a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor, A-790742

A. Molla, D. Kempf, L. L. Klein, 2008, Antimicrobial Agents and Chemotherapy.

2-Pyridyl P1'-substituted symmetry-based human immunodeficiency virus protease inhibitors (A-792611 and A-790742) with potential for convenient dosing and reduced side effects.

V. Stoll, A. Molla, D. Kempf, 2009, Journal of medicinal chemistry.

Resistance analysis in the MAGELLAN-1 Study (Part 2): glecaprevir/pibrentasvir therapy in HCV-infected patients who had failed prior DAA regimens containing NS3/4A protease and/or NS5A inhibitors

T. Pilot‐Matias, T. Reisch, F. Mensa, 2017 .

Discovery of fluorobenzimidazole HCV NS5A inhibitors.

T. Pilot‐Matias, J. Randolph, D. Beno, 2016, Bioorganic & medicinal chemistry letters.

Pooled resistance analysis in HCV genotype 1–6-infected patients treated with glecaprevir/pibrentasvir in phase 2 and 3 clinical trials

T. Pilot‐Matias, T. Reisch, W. Xie, 2017 .

Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials

T. Reisch, W. Xie, F. Mensa, 2018, Antimicrobial Agents and Chemotherapy.

Analysis of HCV Genotype 2 and 3 Variants in Patients Treated with Combination Therapy of Next Generation HCV Direct-Acting Antiviral Agents ABT-493 and ABT-530

J. Kort, T. Reisch, Stanley Wang, 2016 .

Medicinal Chemistry and Drug Design

R. Thaimattam, S. Khanna, A. Leite, 2022 .

Reaction of 2-Mono- and 2,2-Disubstituted 1,3-Dioxolanes with 1-Ethyl-3-hexylaluminacyclopentane

V. Dokichev, L. Spirikhin, T. Dekhtyar, 2004 .